Atezolizumab Dosage

Medically reviewed on May 5, 2017.

Usual Adult Dose for Non-Small Cell Lung Cancer

1200 mg IV over 60 minutes every 3 weeks until disease progression or unacceptable toxicity

Comments:
-If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
-Do not administer this drug as an IV push or bolus.

Uses:
-Urothelial Carcinoma: For the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering 5% or greater of the tumor area), OR are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression, OR have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy
-Metastatic Non-Small Cell Lung Cancer: For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving this drug

Usual Adult Dose for Urothelial Carcinoma

1200 mg IV over 60 minutes every 3 weeks until disease progression or unacceptable toxicity

Comments:
-If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
-Do not administer this drug as an IV push or bolus.

Uses:
-Urothelial Carcinoma: For the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering 5% or greater of the tumor area), OR are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression, OR have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy
-Metastatic Non-Small Cell Lung Cancer: For the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving this drug

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Dose Modifications:
No dose reductions of this drug are recommended.

PNEUMONITIS:
-Grade 2: Withhold dose until Grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg (or equivalent) per day.
-Grade 3 or 4: Permanently discontinue therapy.
HEPATITIS:
-AST or ALT more than 3 and up to 8 times the upper limit of normal (ULN) or total bilirubin more than 1.5 and up to 3 x ULN: Withhold dose until Grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg (or equivalent) per day.
-AST or ALT more than 8 times the upper limit of normal or total bilirubin more than 3 times the upper limit of normal: Permanently discontinue therapy.
COLITIS/DIARRHEA:
-Grade 2 or 3: Withhold dose until Grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg (or equivalent) per day.
-Grade 4: Permanently discontinue therapy.
ENDOCRINOPATHIES (including but not limited to hypophysitis, adrenal insufficiency, hyperthyroidism, and type 1 diabetes mellitus):
Grade 2, 3, or 4: Withhold dose until Grade 1 or resolved and clinically stable on hormone replacement therapy.
OTHER IMMUNE-MEDIATED ADVERSE REACTIONS INVOLVING A MAJOR ORGAN:
-Grade 3: Withhold dose until Grade 1 or resolved and corticosteroid dose is less than or equal to prednisone 10 mg (or equivalent) per day.
-Grade 4: Permanently discontinue therapy.
INFECTIONS:
-Grade 3 or 4: Withhold dose until Grade 1 or resolved.
INFUSION-RELATED REACTIONS:
-Grade 1 or 2: Interrupt or slow the rate of infusion.
-Grade 3 or 4: Permanently discontinue therapy.
PERSISTENT GRADE 2 OR 3 ADVERSE REACTION (excluding endocrinopathies):
-Grade 2 or 3 adverse reaction that does not recover to Grade 0 or 1 within 12 weeks after the last dose: Permanently discontinue therapy.
INABILITY TO TAPER CORTICOSTEROID:
-Inability to reduce to 10 mg (or equivalent) per day or less within 12 weeks after the last dose: Permanently discontinue therapy.
RECURRENT GRADE 3 OR 4 ADVERSE REACTION:
-Recurrent Grade 3 or 4 (severe or life-threatening) adverse reaction: Permanently discontinue therapy.

Precautions

CONTRAINDICATIONS:
-None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Administer the initial infusion over 60 minutes through an IV line with or without a sterile, non-pyrogenic, low-protein binding in-line filter (pore size of 0.2 to 0.22 micron).
-If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes.
-Do not coadminister other drugs through the same IV line.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer